MAZE THERAPEUTICS

Serial Number 88140219
Registration 6091697
700

Registration Progress

Application Filed
Oct 2, 2018
Under Examination
Apr 30, 2019
Approved for Publication
Mar 5, 2019
Published for Opposition
Mar 5, 2019
Registered
Jun 30, 2020

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-30)
Due: Jun 30, 2026 234 days

Trademark Image

MAZE THERAPEUTICS

Basic Information

Serial Number
88140219
Registration Number
6091697
Filing Date
October 2, 2018
Registration Date
June 30, 2020
Published for Opposition
March 5, 2019
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 30, 2020
Registration
Registered
Classes
042

Rights Holder

Maze Therapeutics, Inc.

03
Address
171 Oyster Point Boulevard, Suite 300
San Francisco, CA 94080

Ownership History

Maze Therapeutics, Inc.

Original Applicant
03
San Francisco, CA

Maze Therapeutics, Inc.

Owner at Publication
03
San Francisco, CA

Maze Therapeutics, Inc.

Original Registrant
03
San Francisco, CA

Legal Representation

Attorney
Joyce Liou

USPTO Deadlines

Next Deadline
234 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-06-30)
Due Date
June 30, 2026
Grace Period Ends
December 30, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

32 events
Date Code Type Description Documents
Jun 30, 2025 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
May 20, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
May 20, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
May 20, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
May 20, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
May 20, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 30, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 28, 2020 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
May 27, 2020 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
May 13, 2020 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 13, 2020 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Apr 29, 2020 IUAF S USE AMENDMENT FILED Loading...
Apr 29, 2020 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Nov 1, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 30, 2019 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 30, 2019 EXT1 S SOU EXTENSION 1 FILED Loading...
Oct 30, 2019 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 15, 2019 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Aug 15, 2019 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Apr 30, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 5, 2019 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 5, 2019 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 13, 2019 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 30, 2019 ALIE A ASSIGNED TO LIE Loading...
Jan 15, 2019 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 15, 2019 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 15, 2019 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 15, 2019 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jan 15, 2019 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jan 14, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 10, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 5, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Pharmaceutical research and development services; research in the field of genetic modifier therapeutics
First Use Anywhere: 20181100
First Use in Commerce: 20181100

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"